Great_老虎社区_美港股上老虎

SMLim
2021-12-10

Great

3 High-Growth Stocks That Are Screaming Buys in December<blockquote>12 月份值得买入的 3 只高增长股票</blockquote>

Now is a good time to be greedy and buy up these depressed stocks.

3 High-Growth Stocks That Are Screaming Buys in December<blockquote>12 月份值得买入的 3 只高增长股票</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":605199228,"tweetId":"605199228","gmtCreate":1639125586763,"gmtModify":1639125588843,"author":{"id":3586259427226842,"idStr":"3586259427226842","authorId":3586259427226842,"authorIdStr":"3586259427226842","name":"SMLim","avatar":"https://static.tigerbbs.com/b84ccf92cfb9ec3d527d12880bb472db","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":49,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Great</body></html>","htmlText":"<html><head></head><body>Great</body></html>","text":"Great","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/605199228","repostId":1147480652,"repostType":4,"repost":{"id":"1147480652","kind":"news","pubTimestamp":1639125342,"share":"https://www.laohunote.com/m/news/1147480652?lang=zh_CN&edition=full","pubTime":"2021-12-10 16:35","market":"us","language":"en","title":"3 High-Growth Stocks That Are Screaming Buys in December<blockquote>12 月份值得买入的 3 只高增长股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1147480652","media":"Motley Fool","summary":"Now is a good time to be greedy and buy up these depressed stocks.","content":"If you're looking to do some Christmas shopping on stocks, there are some incredibly good deals out there right now. The market isn't crashing, but some stocks have been struggling of late that you likely won't regret adding to your portfolio today if you're a long-term investor.<blockquote>如果你想在圣诞节购买股票，现在有一些非常好的交易。市场并没有崩盘，但一些股票最近一直在挣扎，如果您是长期投资者，您可能不会后悔今天将其添加到您的投资组合中。</blockquote> Shares of&nbsp;Jazz Pharmaceuticals,DocuSign,and&nbsp;Beyond Meat&nbsp;haven't been this cheap in months. And all these businesses have the potential to generate some strong growth numbers in the months and years ahead, which could mean great returns for you.<blockquote>股份爵士制药,文档签名,和Beyond Meat已经几个月没这么便宜了。所有这些业务都有可能在未来几个月和几年内产生一些强劲的增长数据，这可能意味着您将获得丰厚的回报。</blockquote> <img src=\"https://static.tigerbbs.com/2aaa8c5069132f2d41beafbfbef0705f\" tg-width=\"2000\" tg-height=\"1334\" width=\"100%\" height=\"auto\">Image source: Getty Images<blockquote>图片来源：盖蒂图片社</blockquote> 1. Jazz Pharmaceuticals<blockquote>1. 爵士制药</blockquote> Healthcare company&nbsp;Jazz Pharmaceuticals is trading around its 52-week low, down 25% year to date even as the&nbsp;S&amp;P 500&nbsp;is up 22%. In February, the company announced it was acquiring GW Pharmaceuticals, which makes Epidiolex, a cannabis-based drug that treats seizures. Softness in the cannabis market (due to a disappointing pace in legalization) may in part be affecting the shares.<blockquote>医疗保健公司 Jazz Pharmaceuticals 的股价徘徊在 52 周低点附近，今年迄今已下跌 25%，尽管标普500上涨22%。今年 2 月，该公司宣布收购 GW Pharmaceuticals，该公司生产 Epidiolex，一种治疗癫痫发作的大麻药物。大麻市场的疲软（由于令人失望的合法化步伐）可能在一定程度上影响了股价。</blockquote> Yet, the company still has promise. Jazz reported its latest quarterly results in November, and revenue rose 39% year over year to $838 million. Over half of that came from products that were either new or just acquired, such as Epidiolex. Its sales rose a robust 21% despite investor concerns.<blockquote>然而，该公司仍有希望。爵士乐在11月份公布了最新的季度业绩，收入同比增长39%，达到8.38亿美元。其中一半以上来自新产品或刚刚收购的产品，例如 Epidiolex。尽管投资者担忧，其销售额仍强劲增长 21%。</blockquote> In fact, Epidiolex is what makes Jazz a promising buy here as the company is looking at new indications for it; plus, it is rolling out Epidiolex to new countries in Europe. Both moves could bolster the drug's sales over the long term.<blockquote>事实上，Epidiolex 使 Jazz 成为这里一个有前途的买家，因为该公司正在寻找新的适应症；此外，它正在向欧洲的新国家推出Epidiolex。从长远来看，这两项举措都可能提振该药物的销售。</blockquote> Prospects for long-term profitability also look strong. The company has generated impressive gross margins of 82% or better in each of the past four quarters. Although its bottom line has fallen into the red after the acquisition of GW Pharma, that's not where investors should expect the company to stay. Jazz could be a steal of a deal right now.<blockquote>长期盈利前景看起来也很强劲。该公司在过去四个季度中的每个季度都取得了令人印象深刻的 82% 或更高的毛利率。尽管在收购 GW Pharma 后，其利润已陷入亏损，但这并不是投资者应该期望该公司停留的地方。爵士队现在可能是一笔划算的交易。</blockquote> 2. DocuSign<blockquote>2. 文档签名</blockquote> Anytime a stock&nbsp;falls more than 40% in a&nbsp;single day, it's worth asking whether the market overreacted. That's what looks to have happened with DocuSign. The company beat expectations when it reported third-quarter results last week. Sales for the period ended Oct. 31 soared 42% year over year to $545.5 million. The company also regularly boasts a gross profit of close to 80%.<blockquote>任何时候股票下跌超过 40%单日，值得追问的是市场是否反应过度。DocuSign似乎就是这样。该公司上周公布第三季度业绩时超出了预期。截至 10 月 31 日的销售额同比飙升 42%，达到 5.455 亿美元。该公司还经常吹嘘毛利润接近80%。</blockquote> Yet, that wasn't enough for investors. A sell-off ensued as the tech company provided fourth-quarter revenue guidance of $557 million to $563 million -- and that fell well shy of the $574 million that analysts were expecting. While the estimate is below analysts' figures, that hardly seems to be a reason to warrant such an incredible drop in price.<blockquote>然而，这对投资者来说还不够。这家科技公司提供的第四季度收入指引为 5.57 亿至 5.63 亿美元，随后出现抛售，远低于分析师预期的 5.74 亿美元。虽然这一估计低于分析师的数字，但这似乎很难成为价格出现如此令人难以置信的下跌的理由。</blockquote> Unfortunately, in the era of meme stocks, where companies with questionable growth prospects such as&nbsp;AMC Entertainment&nbsp;can skyrocket over 1,000% -- mainly on hype from retail investors -- high-quality businesses like DocuSign can also fall drastically without a good reason. Such a steep sell-off due to one quarter's guidance is the epitome of short-term thinking.<blockquote>不幸的是，在模因股票时代，增长前景可疑的公司，例如AMC院线可能会飙升超过 1,000%（主要是由于散户投资者的炒作），像 DocuSign 这样的高质量企业也可能在没有充分理由的情况下大幅下跌。由于一个季度的指导而出现如此大幅的抛售，是短期思维的缩影。</blockquote> DocuSign will likely see demand subside a bit as people return to the office and are no longer relying as much on digital signatures. However, that doesn't mean its growth is over. Analysts from Fortune Business Insights project that the global digital signature market will grow at a compound annual rate of 28.9% through 2027.<blockquote>随着人们重返办公室，不再如此依赖数字签名，DocuSign的需求可能会有所下降。然而，这并不意味着它的增长已经结束。Fortune Business Insights 的分析师预计，到 2027 年，全球数字签名市场的复合年增长率将达到 28.9%。</blockquote> So despite the bearishness, the sky isn't falling for DocuSign, and it looks like it could be a bargain buy right now. Although the stock has bounced up from the lows it hit last week, it's still around levels not seen since June 2020.<blockquote>因此，尽管看跌，DocuSign 的天空并没有塌下来，看起来现在可能是一个便宜货。尽管该股已从上周触及的低点反弹，但仍处于 2020 年 6 月以来的最高水平。</blockquote> 3. Beyond Meat<blockquote>3. Beyond Meat</blockquote> Another stock that has struggled after releasing earnings is Beyond Meat. At just over $70, the stock is trading near its 52-week lows, having fallen 43% this year.It's not a huge surprise given that the company has an unfortunate trend of missing earnings expectations. Yet, Beyond Meat is a great recovery stock to own as economies see a return to normal and COVID-19 no longer impacts demand for its products or disrupts the supply chain.<blockquote>另一只在发布财报后陷入困境的股票是Beyond Meat。该股股价略高于 70 美元，接近 52 周低点，今年已下跌 43%。考虑到该公司不幸出现了未达盈利预期的趋势，这并不奇怪。然而，随着经济恢复正常，新冠肺炎不再影响对其产品的需求或扰乱供应链，Beyond Meat是一只值得持有的复苏股票。</blockquote> In 2019, the company's sales of $298 million were more than triple the $88 million it reported in 2018. And in 2020, sales rose further to $407 million but at a much lower growth rate of 37%. For the latest quarter ended Oct. 2, net revenue increased just 13% to $106 million -- and in the U.S. market, sales were actually down 14%. It was the company's international operations that kept the overall numbers in the green (rising by an impressive 143%).<blockquote>2019年，该公司2.98亿美元的销售额是2018年8800万美元的三倍多。2020 年，销售额进一步上升至 4.07 亿美元，但增长率要低得多，为 37%。截至 10 月 2 日的最新季度，净收入仅增长 13%，达到 1.06 亿美元，而在美国市场，销售额实际上下降了 14%。正是该公司的国际业务使整体数字保持绿色（增长了令人印象深刻的 143%）。</blockquote> However, the company's performance should improve with a return to normalcy. In addition, Beyond Meat has new products and deals that could propel it to even greater heights than before. It is supplying fast-food giant&nbsp;McDonald's&nbsp;with the patty for its McPlant burger, which could be a boon for the business if it proves to be successful. Plus, it has a joint venture with soft-drink maker&nbsp;PepsiCo&nbsp;to develop new products. Beyond Meat also recently launched meatless chicken tenders.<blockquote>然而，随着恢复正常，公司业绩应该会有所改善。此外，Beyond Meat还有新产品和交易，可以将其推向比以前更高的高度。它正在向快餐巨头供货麦当劳为其 McPlant 汉堡配上馅饼，如果事实证明它是成功的，这可能会给该业务带来好处。此外，它还与一家软饮料制造商成立了一家合资企业百事可乐开发新产品。Beyond Meat最近也推出了无肉鸡肉。</blockquote> Things may look grim in the short term for Beyond Meat, but there are many catalysts out there that could make its stock price today look incredibly cheap in a year or two.<blockquote>Beyond Meat的短期内情况可能会很严峻，但有许多催化剂可能会使其股价在一两年内看起来非常便宜。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 High-Growth Stocks That Are Screaming Buys in December<blockquote>12 月份值得买入的 3 只高增长股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 High-Growth Stocks That Are Screaming Buys in December<blockquote>12 月份值得买入的 3 只高增长股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-12-10 16:35\n\n</h4>\n</header>\n<article>\nIf you're looking to do some Christmas shopping on stocks, there are some incredibly good deals out there right now. The market isn't crashing, but some stocks have been struggling of late that you likely won't regret adding to your portfolio today if you're a long-term investor.<blockquote>如果你想在圣诞节购买股票，现在有一些非常好的交易。市场并没有崩盘，但一些股票最近一直在挣扎，如果您是长期投资者，您可能不会后悔今天将其添加到您的投资组合中。</blockquote> Shares of&nbsp;Jazz Pharmaceuticals,DocuSign,and&nbsp;Beyond Meat&nbsp;haven't been this cheap in months. And all these businesses have the potential to generate some strong growth numbers in the months and years ahead, which could mean great returns for you.<blockquote>股份爵士制药,文档签名,和Beyond Meat已经几个月没这么便宜了。所有这些业务都有可能在未来几个月和几年内产生一些强劲的增长数据，这可能意味着您将获得丰厚的回报。</blockquote> <img src=\"https://static.tigerbbs.com/2aaa8c5069132f2d41beafbfbef0705f\" tg-width=\"2000\" tg-height=\"1334\" width=\"100%\" height=\"auto\">Image source: Getty Images<blockquote>图片来源：盖蒂图片社</blockquote> 1. Jazz Pharmaceuticals<blockquote>1. 爵士制药</blockquote> Healthcare company&nbsp;Jazz Pharmaceuticals is trading around its 52-week low, down 25% year to date even as the&nbsp;S&amp;P 500&nbsp;is up 22%. In February, the company announced it was acquiring GW Pharmaceuticals, which makes Epidiolex, a cannabis-based drug that treats seizures. Softness in the cannabis market (due to a disappointing pace in legalization) may in part be affecting the shares.<blockquote>医疗保健公司 Jazz Pharmaceuticals 的股价徘徊在 52 周低点附近，今年迄今已下跌 25%，尽管标普500上涨22%。今年 2 月，该公司宣布收购 GW Pharmaceuticals，该公司生产 Epidiolex，一种治疗癫痫发作的大麻药物。大麻市场的疲软（由于令人失望的合法化步伐）可能在一定程度上影响了股价。</blockquote> Yet, the company still has promise. Jazz reported its latest quarterly results in November, and revenue rose 39% year over year to $838 million. Over half of that came from products that were either new or just acquired, such as Epidiolex. Its sales rose a robust 21% despite investor concerns.<blockquote>然而，该公司仍有希望。爵士乐在11月份公布了最新的季度业绩，收入同比增长39%，达到8.38亿美元。其中一半以上来自新产品或刚刚收购的产品，例如 Epidiolex。尽管投资者担忧，其销售额仍强劲增长 21%。</blockquote> In fact, Epidiolex is what makes Jazz a promising buy here as the company is looking at new indications for it; plus, it is rolling out Epidiolex to new countries in Europe. Both moves could bolster the drug's sales over the long term.<blockquote>事实上，Epidiolex 使 Jazz 成为这里一个有前途的买家，因为该公司正在寻找新的适应症；此外，它正在向欧洲的新国家推出Epidiolex。从长远来看，这两项举措都可能提振该药物的销售。</blockquote> Prospects for long-term profitability also look strong. The company has generated impressive gross margins of 82% or better in each of the past four quarters. Although its bottom line has fallen into the red after the acquisition of GW Pharma, that's not where investors should expect the company to stay. Jazz could be a steal of a deal right now.<blockquote>长期盈利前景看起来也很强劲。该公司在过去四个季度中的每个季度都取得了令人印象深刻的 82% 或更高的毛利率。尽管在收购 GW Pharma 后，其利润已陷入亏损，但这并不是投资者应该期望该公司停留的地方。爵士队现在可能是一笔划算的交易。</blockquote> 2. DocuSign<blockquote>2. 文档签名</blockquote> Anytime a stock&nbsp;falls more than 40% in a&nbsp;single day, it's worth asking whether the market overreacted. That's what looks to have happened with DocuSign. The company beat expectations when it reported third-quarter results last week. Sales for the period ended Oct. 31 soared 42% year over year to $545.5 million. The company also regularly boasts a gross profit of close to 80%.<blockquote>任何时候股票下跌超过 40%单日，值得追问的是市场是否反应过度。DocuSign似乎就是这样。该公司上周公布第三季度业绩时超出了预期。截至 10 月 31 日的销售额同比飙升 42%，达到 5.455 亿美元。该公司还经常吹嘘毛利润接近80%。</blockquote> Yet, that wasn't enough for investors. A sell-off ensued as the tech company provided fourth-quarter revenue guidance of $557 million to $563 million -- and that fell well shy of the $574 million that analysts were expecting. While the estimate is below analysts' figures, that hardly seems to be a reason to warrant such an incredible drop in price.<blockquote>然而，这对投资者来说还不够。这家科技公司提供的第四季度收入指引为 5.57 亿至 5.63 亿美元，随后出现抛售，远低于分析师预期的 5.74 亿美元。虽然这一估计低于分析师的数字，但这似乎很难成为价格出现如此令人难以置信的下跌的理由。</blockquote> Unfortunately, in the era of meme stocks, where companies with questionable growth prospects such as&nbsp;AMC Entertainment&nbsp;can skyrocket over 1,000% -- mainly on hype from retail investors -- high-quality businesses like DocuSign can also fall drastically without a good reason. Such a steep sell-off due to one quarter's guidance is the epitome of short-term thinking.<blockquote>不幸的是，在模因股票时代，增长前景可疑的公司，例如AMC院线可能会飙升超过 1,000%（主要是由于散户投资者的炒作），像 DocuSign 这样的高质量企业也可能在没有充分理由的情况下大幅下跌。由于一个季度的指导而出现如此大幅的抛售，是短期思维的缩影。</blockquote> DocuSign will likely see demand subside a bit as people return to the office and are no longer relying as much on digital signatures. However, that doesn't mean its growth is over. Analysts from Fortune Business Insights project that the global digital signature market will grow at a compound annual rate of 28.9% through 2027.<blockquote>随着人们重返办公室，不再如此依赖数字签名，DocuSign的需求可能会有所下降。然而，这并不意味着它的增长已经结束。Fortune Business Insights 的分析师预计，到 2027 年，全球数字签名市场的复合年增长率将达到 28.9%。</blockquote> So despite the bearishness, the sky isn't falling for DocuSign, and it looks like it could be a bargain buy right now. Although the stock has bounced up from the lows it hit last week, it's still around levels not seen since June 2020.<blockquote>因此，尽管看跌，DocuSign 的天空并没有塌下来，看起来现在可能是一个便宜货。尽管该股已从上周触及的低点反弹，但仍处于 2020 年 6 月以来的最高水平。</blockquote> 3. Beyond Meat<blockquote>3. Beyond Meat</blockquote> Another stock that has struggled after releasing earnings is Beyond Meat. At just over $70, the stock is trading near its 52-week lows, having fallen 43% this year.It's not a huge surprise given that the company has an unfortunate trend of missing earnings expectations. Yet, Beyond Meat is a great recovery stock to own as economies see a return to normal and COVID-19 no longer impacts demand for its products or disrupts the supply chain.<blockquote>另一只在发布财报后陷入困境的股票是Beyond Meat。该股股价略高于 70 美元，接近 52 周低点，今年已下跌 43%。考虑到该公司不幸出现了未达盈利预期的趋势，这并不奇怪。然而，随着经济恢复正常，新冠肺炎不再影响对其产品的需求或扰乱供应链，Beyond Meat是一只值得持有的复苏股票。</blockquote> In 2019, the company's sales of $298 million were more than triple the $88 million it reported in 2018. And in 2020, sales rose further to $407 million but at a much lower growth rate of 37%. For the latest quarter ended Oct. 2, net revenue increased just 13% to $106 million -- and in the U.S. market, sales were actually down 14%. It was the company's international operations that kept the overall numbers in the green (rising by an impressive 143%).<blockquote>2019年，该公司2.98亿美元的销售额是2018年8800万美元的三倍多。2020 年，销售额进一步上升至 4.07 亿美元，但增长率要低得多，为 37%。截至 10 月 2 日的最新季度，净收入仅增长 13%，达到 1.06 亿美元，而在美国市场，销售额实际上下降了 14%。正是该公司的国际业务使整体数字保持绿色（增长了令人印象深刻的 143%）。</blockquote> However, the company's performance should improve with a return to normalcy. In addition, Beyond Meat has new products and deals that could propel it to even greater heights than before. It is supplying fast-food giant&nbsp;McDonald's&nbsp;with the patty for its McPlant burger, which could be a boon for the business if it proves to be successful. Plus, it has a joint venture with soft-drink maker&nbsp;PepsiCo&nbsp;to develop new products. Beyond Meat also recently launched meatless chicken tenders.<blockquote>然而，随着恢复正常，公司业绩应该会有所改善。此外，Beyond Meat还有新产品和交易，可以将其推向比以前更高的高度。它正在向快餐巨头供货麦当劳为其 McPlant 汉堡配上馅饼，如果事实证明它是成功的，这可能会给该业务带来好处。此外，它还与一家软饮料制造商成立了一家合资企业百事可乐开发新产品。Beyond Meat最近也推出了无肉鸡肉。</blockquote> Things may look grim in the short term for Beyond Meat, but there are many catalysts out there that could make its stock price today look incredibly cheap in a year or two.<blockquote>Beyond Meat的短期内情况可能会很严峻，但有许多催化剂可能会使其股价在一两年内看起来非常便宜。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/12/09/3-high-growth-stocks-that-are-screaming-buys-in-de/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","DOCU":"Docusign","JAZZ":"爵士制药"},"source_url":"https://www.fool.com/investing/2021/12/09/3-high-growth-stocks-that-are-screaming-buys-in-de/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147480652","content_text":"If you're looking to do some Christmas shopping on stocks, there are some incredibly good deals out there right now. The market isn't crashing, but some stocks have been struggling of late that you likely won't regret adding to your portfolio today if you're a long-term investor.\nShares of Jazz Pharmaceuticals,DocuSign,and Beyond Meat haven't been this cheap in months. And all these businesses have the potential to generate some strong growth numbers in the months and years ahead, which could mean great returns for you.\nImage source: Getty Images\n1. Jazz Pharmaceuticals\nHealthcare company Jazz Pharmaceuticals is trading around its 52-week low, down 25% year to date even as the S&P 500 is up 22%. In February, the company announced it was acquiring GW Pharmaceuticals, which makes Epidiolex, a cannabis-based drug that treats seizures. Softness in the cannabis market (due to a disappointing pace in legalization) may in part be affecting the shares.\nYet, the company still has promise. Jazz reported its latest quarterly results in November, and revenue rose 39% year over year to $838 million. Over half of that came from products that were either new or just acquired, such as Epidiolex. Its sales rose a robust 21% despite investor concerns.\nIn fact, Epidiolex is what makes Jazz a promising buy here as the company is looking at new indications for it; plus, it is rolling out Epidiolex to new countries in Europe. Both moves could bolster the drug's sales over the long term.\nProspects for long-term profitability also look strong. The company has generated impressive gross margins of 82% or better in each of the past four quarters. Although its bottom line has fallen into the red after the acquisition of GW Pharma, that's not where investors should expect the company to stay. Jazz could be a steal of a deal right now.\n2. DocuSign\nAnytime a stock falls more than 40% in a single day, it's worth asking whether the market overreacted. That's what looks to have happened with DocuSign. The company beat expectations when it reported third-quarter results last week. Sales for the period ended Oct. 31 soared 42% year over year to $545.5 million. The company also regularly boasts a gross profit of close to 80%.\nYet, that wasn't enough for investors. A sell-off ensued as the tech company provided fourth-quarter revenue guidance of $557 million to $563 million -- and that fell well shy of the $574 million that analysts were expecting. While the estimate is below analysts' figures, that hardly seems to be a reason to warrant such an incredible drop in price.\nUnfortunately, in the era of meme stocks, where companies with questionable growth prospects such as AMC Entertainment can skyrocket over 1,000% -- mainly on hype from retail investors -- high-quality businesses like DocuSign can also fall drastically without a good reason. Such a steep sell-off due to one quarter's guidance is the epitome of short-term thinking.\nDocuSign will likely see demand subside a bit as people return to the office and are no longer relying as much on digital signatures. However, that doesn't mean its growth is over. Analysts from Fortune Business Insights project that the global digital signature market will grow at a compound annual rate of 28.9% through 2027.\nSo despite the bearishness, the sky isn't falling for DocuSign, and it looks like it could be a bargain buy right now. Although the stock has bounced up from the lows it hit last week, it's still around levels not seen since June 2020.\n3. Beyond Meat\nAnother stock that has struggled after releasing earnings is Beyond Meat. At just over $70, the stock is trading near its 52-week lows, having fallen 43% this year.It's not a huge surprise given that the company has an unfortunate trend of missing earnings expectations. Yet, Beyond Meat is a great recovery stock to own as economies see a return to normal and COVID-19 no longer impacts demand for its products or disrupts the supply chain.\nIn 2019, the company's sales of $298 million were more than triple the $88 million it reported in 2018. And in 2020, sales rose further to $407 million but at a much lower growth rate of 37%. For the latest quarter ended Oct. 2, net revenue increased just 13% to $106 million -- and in the U.S. market, sales were actually down 14%. It was the company's international operations that kept the overall numbers in the green (rising by an impressive 143%).\nHowever, the company's performance should improve with a return to normalcy. In addition, Beyond Meat has new products and deals that could propel it to even greater heights than before. It is supplying fast-food giant McDonald's with the patty for its McPlant burger, which could be a boon for the business if it proves to be successful. Plus, it has a joint venture with soft-drink maker PepsiCo to develop new products. Beyond Meat also recently launched meatless chicken tenders.\nThings may look grim in the short term for Beyond Meat, but there are many catalysts out there that could make its stock price today look incredibly cheap in a year or two.","news_type":1,"symbols_score_info":{"BYND":0.9,"JAZZ":0.9,"DOCU":0.9}},"isVote":1,"tweetType":1,"viewCount":3183,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

3 High-Growth Stocks That Are Screaming Buys in December<blockquote>12 月份值得买入的 3 只高增长股票</blockquote>

评论（2）

热议股票